Dyne Therapeutics, Inc.
DYNDrugs in Pipeline
4
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 2 past
No catalysts found.
How DYN's past catalysts played out
zeleciment basivarsen (DYNE-101)
Myotonic Dystrophy Type 1 (DM1)
Zeleciment Rostudirsen (DYNE-251)
Duchenne Muscular Dystrophy (DMD)
DYNE-101
Myotonic Dystrophy Type 1 (DM1)
DYNE-251
Duchenne Muscular Dystrophy (DMD)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
zeleciment basivarsen (DYNE-101) | Phase 3 | Myotonic Dystrophy Type 1 (DM1) | - | - |
Zeleciment Rostudirsen (DYNE-251) | Phase 3 | Duchenne Muscular Dystrophy (DMD) | - | - |
DYNE-101 | Phase 2 | Myotonic Dystrophy Type 1 (DM1) | - | - |
DYNE-251 | Phase 2 | Duchenne Muscular Dystrophy (DMD) | - | - |
Frequently asked questions
What is in Dyne Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Dyne Therapeutics, Inc.'s (DYN) pipeline across Phase 3, Phase 2. Its lead program is zeleciment basivarsen (DYNE-101) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Dyne Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Dyne Therapeutics, Inc. (DYN) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track DYN biotech catalysts?→
Add DYN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Dyne Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.